NCT00522470

Brief Summary

We aimed to evaluate the effects of rosiglitazone on serum ghrelin and peptide yy levels in diabetic women.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 27, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 29, 2007

Completed
Last Updated

May 9, 2008

Status Verified

May 1, 2008

First QC Date

August 27, 2007

Last Update Submit

May 7, 2008

Conditions

Type 2 Diabetes MellitusObesity

Interventions

rosiglitazoneDRUG

Eligibility Criteria

Age45 Years - 65 Years
Sexfemale
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • newly diagnosed, drug naive women with type 2 diabetes

You may not qualify if:

  • presence of severe cardiovascular disease (eg, New York Heart Association class III or IV congestive heart failure or a history of myocardial infarction or stroke)
  • presence of thyroid, pituitary, nutritional, hepatic, renal, or neoplastic disorders

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Baskent University Hospital Department of Endocrinology

Ankara, Bahçelievler, 06490, Turkey (Türkiye)

Location

Related Publications (1)

  • Berberoglu Z, Yazici AC, Bayraktar N, Demirag NG. Rosiglitazone decreases fasting plasma peptide YY3-36 in type 2 diabetic women: a possible role in weight gain? Acta Diabetol. 2012 Dec;49 Suppl 1:S115-22. doi: 10.1007/s00592-011-0352-3. Epub 2011 Nov 19.

    PMID: 22101910DERIVED

MeSH Terms

Conditions

Diabetes Mellitus, Type 2Obesity

Interventions

Rosiglitazone

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesOverweightOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

ThiazolidinedionesThiazolesSulfur CompoundsOrganic ChemicalsAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Zehra Berberoglu, MD

    Baskent University Faculty of Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

August 27, 2007

First Posted

August 29, 2007

Last Updated

May 9, 2008

Record last verified: 2008-05

Locations

TU(1)